DOI QR코드

DOI QR Code

Mortality and Morbidity and Disease Free Survival after D1 and D2 Gastrectomy for Stomach Adenocarcinomas

  • Talaiezadeh, AH (Department of Surgery, Cancer Research Center, Imam Khomeini Hospital, School of Medicine, Jundishapur University of Medical Sciences) ;
  • Asgari, M (Department of Surgery, Cancer Research Center, Imam Khomeini Hospital, School of Medicine, Jundishapur University of Medical Sciences) ;
  • Zargar, MA (Department of Surgery, Cancer Research Center, Imam Khomeini Hospital, School of Medicine, Jundishapur University of Medical Sciences)
  • Published : 2015.08.03

Abstract

Background: A number of randomized trials addressing alternative operative and multimodality approaches to gastric cancer have characterized early postoperative morbidity and mortality rates. The aim of this study was to compare mortality and morbidity and disease free survival after D1 and D2 gastrectomy for adenocarcinomas of the stomach Materials and Methods: From June 2006 to January 2012, patients were selected according to information of the cancer administrator center of Ahvaz Jundishapur Medical University. The inclusion criteria were age between 20-85 years and histologically proven adenocarcinoma of the stomach without evidence of distant metastasis. Patients were excluded if they had previous or coexisting cancer or disability disease. In this research, D1 was compared to D2 gastrectomy. Results: 131 patients were randomised, 49 allocated to D1 and 82 to D2 gastrectomy. The two groups were comparable for age, sex, site of tumors, and type of resection performed. The overall post-operative morbidity rate was 17.5%. Complications developed in 14.2% of patients after D1 and in 19.5% of patients after D2 gastrectomy (p=0.07). Postoperative mortality rate was 0.8% (one death); it was 2% after D1 and 0% after D2 gastrectomy. In this research disease free-survival after 3 years was 71.2 % with 63.2% after D1 and 76.8% after D2 gasterctomy. Conclusions: This study indicates that D2 gastrectomy with pancreas preservation is not followed by significantly higher morbidity and mortality than D1 resection. Based on the results of present study, D2 resection should be recommended as the standard surgical approach for resectable gastric cancer.

Keywords

References

  1. Cunningham D, Allum WH, Stenning SP, et al (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 355, 11-20. https://doi.org/10.1056/NEJMoa055531
  2. Cuschieri A, Fayers P, Fielding J, et al (1996). Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomized controlled surgical trial. Lancet, 347, 995-9. https://doi.org/10.1016/S0140-6736(96)90144-0
  3. Cuschieri A, Weeden S, Fielding J, et al (1999). Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer, 79, 1522-30. https://doi.org/10.1038/sj.bjc.6690243
  4. Degiuli M, Sasako M, Ponti A, et al (2004). Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer. Br J Cancer, 90, 1727-32.
  5. Ferlay J, Soerjomataram I, Ervik M, et al (2012). Cancer incidence and mortality worldwide: IARC cancerbase No. 11 [Internet]. Lyon, France: international agency for research on cancer; 2013. Available from: http://globocan.iarc.fr. Accessed April 7, 2014.
  6. Hartgrink HH, van de Velde CJ, Putter H, et al (2004). Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol, 22, 2069-77. https://doi.org/10.1200/JCO.2004.08.026
  7. Howlader NA, Krapcho M, Neyman N, et al (2012). Cancer statistics review, 1975-m2010 (Vintage 2010 Populations). bethesda, MD: national cancer institute. Available from: http://seer.cancer.gov/csr/1975_2010_pops09/.
  8. Maruyama K, Sasako M, Kinoshita T, et al (1995). Pancreaspreserving total gastrectomy for proximal gastric cancer. World J Surg, 19, 532-6. https://doi.org/10.1007/BF00294714
  9. Parikh D, Chagla L, Johnson M, et al (1996). D2 gastrectomy: lessons from a prospective audit of the learning curve. Br J Surg, 83, 1595-9. https://doi.org/10.1002/bjs.1800831134
  10. Sasako M, Sano T, Yamamoto S, et al (2008). D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med, 359, 453-62. https://doi.org/10.1056/NEJMoa0707035
  11. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ (2010). surgical treatment of gaytric camcer:15 Year followup result of the randomissed nationwide Duteh D1D2 trial. Lancet Oncol, 11, 439-49. https://doi.org/10.1016/S1470-2045(10)70070-X
  12. Wanebo HJ, Kennedy BJ, Chmiel J, et al (1993). Cancer of the stomach. a patient care study by the American college of surgeons. Am J Surg, 218, 583-92.
  13. Wu CW, Hsiung CA, Lo SS, et al (2006). Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol, 7, 309-15. https://doi.org/10.1016/S1470-2045(06)70623-4
  14. Yu W, Choi GS, Chung HY (2006). Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg, 93, 559-63. https://doi.org/10.1002/bjs.5353